The Regulatory Effect of Su Huang Cough Capsules Combined with Acupoint Patching on Airway Inflammation in Patients with Cough Variant Asthma: A Prospective Randomized Open-Label Clinical Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2026001227

Enrollment

Unknown

Registered

2026-05-14

Start date

2026-05-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cough-variant asthma

Interventions

Conventional treatment group:Inhale budesonide/formoterol 160/4.5 µg, 1 inhalation twice daily

use salbutamol as needed.

Suhuang Zhike capsules Group:Routine treatment + Su Huang Zhi Ke Capsules, 3 capsules, three times daily, orally after meals.

Su Huang Cough Capsule + Acupoint Patch Application Group:Routine treatment + Suhuang Zhike Capsules, 3 capsules three times daily, taken orally after meals + Tianzu (CV 22) and Dazhui (GV 14) acupoin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: a. Age between 18-80 years; b. Meets the diagnostic criteria for CVA in the "Chinese Cough Diagnosis and Treatment Guidelines 2023": dry cough =3 weeks, positive bronchial provocation/dilation test; c. No use of Suhuang Zhike capsules or other traditional Chinese medicine treatments within 1 week prior to enrollment; d. Meets the diagnostic criteria for "wind cough" in traditional Chinese medicine; e. Cough Visual Analog Scale (VAS) =4 points; f. Signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria: a. Coexisting chronic obstructive pulmonary disease (COPD), bronchiectasis, or other pulmonary diseases; b. Severe dysfunction of heart, liver, or kidneys, specifically defined as ALT/AST >1.5 times the upper limit of normal, creatinine > upper limit of normal, inability to tolerate the investigational drug or intervention measures; c. Pregnancy, breastfeeding, or plans for pregnancy; d. Skin damage or allergy at the acupoint application site; e. Allergic reactions to components of Suhuang Zhike capsules (e.g., ephedra, perilla leaf, etc.) or acupoint application drugs (e.g., mustard seed, ginger, etc.); f. Participation in other clinical trials within the past 3 months; g. Patients with mental disorders who are unable to cooperate with the trial process and follow-up requirements.

Design outcomes

Primary

Measure	Time frame
Cough Visual Analog Scale (VAS);TCM Wind-Cough Syndrome Score;	—

Secondary

Measure	Time frame
Pulmonary Function;Recurrence rate;Duration of remission period;	—

Countries

China

Contacts

Public ContactSun Feng

Xinjiang Medical University First Affiliated Hospital

sunfeng_xjmu@163.com18699132109

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026